Just a month after laying off 147 employees and announcing plans to mull “strategic alternatives,” Vor Biopharma Inc.

The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” first quarter 2025 ...

Trafficking and exploitation can be a blind spot for business leaders, putting employees at risk and exposing the ...

Wells Fargo cut the price target for The Trade Desk, Inc. TTD from $74 to $68. Wells Fargo analyst Alec Brondolo downgraded ...

KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader KT-474. This setback was somewhat offset by KYMR’s announcement of an exclusive option and license ...

Gilead Sciences and Kymera Therapeutics have entered into a partnership worth as much as $750m to develop a molecular glue ...

Danish allergy immunotherapy specialist ALK Abello today announced the first market launch of EURneffy (epinephrine) 2mg (the ...

FOSTER CITY, CA & WATERTOWN, MA, USA I June 25, 2025 I Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced ...

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 ...

Gilead Sciences, Inc. and Kymera Therapeutics, Inc., have entered into an exclusive option and license agreement for ...